Blue Wolf Capital Acquires Seven Recipharm OSD Sites and Agrees to Buy Synerlab to Create New CDMO Platform
April 2, 2024
Blue Wolf Capital Partners has agreed to acquire seven oral solid dosage (OSD) manufacturing and development facilities from Recipharm (located in Sweden, France and Spain) and has also agreed, subject to regulatory approvals, to acquire Synerlab, a Strasbourg-based CDMO. The transactions are intended to form a new independent CDMO platform (headquartered in the UK) that expands Blue Wolf's pharmaceutical manufacturing capabilities and commercial reach across Europe.
- Targets
- Recipharm OSD sites (Solna; Stängnäs; Höganäs; Karlskoga; Uppsala OTC Development; Pessac; Parets), Synerlab
- Sellers
- Recipharm
- Industry
- Pharmaceuticals
- Location
- Sweden
- Transaction Type
- Divestiture
Explore More
Related Acquisitions
-
Siegfried Holding AG Acquires Noramco, Extractas Biosciences, and Purisys from SK Capital Partners
January 27, 2026
Healthcare Services
Siegfried Holding AG has acquired Noramco, Extractas Biosciences, and Purisys (the Noramco Group) from affiliates advised by SK Capital Partners. The deal added small-molecule API/CDMO drug substance capabilities to Siegfried, while SK Capital retained Halo Pharmaceuticals as a standalone finished-dose-form CDMO.
-
Recipharm AB Acquires Vibalogics from Ampersand Capital Partners
February 18, 2022
Biotechnology
Recipharm AB, a global CDMO based in Sweden, has agreed to acquire Vibalogics, a virotherapy-focused CDMO and Ampersand Capital Partners portfolio company. The deal expands Recipharm's capabilities into viral vaccines, viral vectors and oncolytic virus manufacturing while Vibalogics will continue operating from its Boxborough, MA and Cuxhaven, Germany facilities.
-
Recro Pharma Acquires IRISYS (San Diego)
August 13, 2021
Pharmaceuticals
Recro Pharma (NASDAQ: REPH) acquired San Diego–based CDMO IRISYS for approximately $49.85 million in cash, stock and a seller promissory note, transforming Recro into a bi‑coastal, full‑service CDMO. The acquisition expands Recro's capabilities (including aseptic fill/finish and lyophilization), diversifies its client base and adds near‑term revenue and backlog.
-
SK Capital Acquires Catalent's Blow‑Fill‑Seal Sterile CDMO Business (Woodstock Sterile Solutions)
March 31, 2021
Pharmaceuticals
Funds managed by SK Capital Partners completed the acquisition of Catalent Pharma Solutions' Blow‑Fill‑Seal (BFS) sterile CDMO business and relaunched the business as Woodstock Sterile Solutions. The single‑site Woodstock, Illinois operation will operate independently under new CEO Paul Josephs, supporting global pharmaceutical and biologics customers; Catalent was the seller and debt financing was provided by Cerberus Business Finance.
-
Omnicell Acquires Pharmaceutical Strategies Group's 340B Link Business from Blue Wolf Capital
October 2, 2020
Healthcare Services
Omnicell, Inc. has acquired Pharmaceutical Strategies Group's market-leading 340B Link business from Blue Wolf Capital Partners for $225 million. The deal, which completes Blue Wolf's exit of PSG from Fund II, expands Omnicell's medication management and data-enabled services for hospitals and pharmacies.
-
Servier Acquires Symphogen A/S from Novo Holdings and Other Owners
April 3, 2020
Biotechnology
Servier has acquired 100% of the share capital of Symphogen A/S from Novo Holdings and the remaining owners, taking ownership of the Danish therapeutic antibody discovery and early biologics development company. The deal brings Symphogen’s antibody discovery platform and CMC biologics development capabilities into Servier’s oncology and immuno-oncology R&D efforts to strengthen its biologics pipeline and development capacity.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.